论文部分内容阅读
【目的】评价泰素蒂(TXT)联合顺铂(DDP)作为一线方案治疗晚期非小细胞肺癌(NSCLC)的疗效和毒副作用。【方法】入组晚期NSCLC患者30例,均为初次化疗,全部患者均有可测量或可评价指标.给药方法:TXT75mg/m2静脉滴注,第1天;DDP100mg/m2静脉滴注,第1天或25mg/m2静脉滴注,第1～4天;21d为1个周期。疗效每2周期评价1次;毒副作用每周期均评价。化疗4～6个疗程;毒副反应不能耐受或疾病进展均停药或改其他方案。【结果】30例患者共接受治疗112个周期,中位数为4个周期。CR1例(3.33%),PR9例(30.00%),SD15例(50.00%),PD5例(16.67%),有效率为33.33%(10/30),中位治疗至疾病进展时间为7.5月。1年生存率50.33%(16/30)。Ⅲ、Ⅳ度不良毒副作用发生率为脱发26.67%;粒细胞减少20.00%;恶心呕吐16.67%;血小板减少3.33%。【结论】TXT联合DDP作为一线方案治疗晚期NSCLC疗效满意、耐受性好,值得临床应用。
【Objective】 To evaluate the efficacy and toxicity of paclitaxel (TXT) combined with cisplatin (DDP) as a first-line regimen in the treatment of advanced non-small cell lung cancer (NSCLC). 【Methods】 Thirty patients with advanced NSCLC were enrolled in this study. All of them were primary chemotherapy, and all patients had measurable or evaluable indexes.Dotaining methods: TXT75mg / m2 intravenous drip on day 1, DDP100mg / m2 intravenous infusion, 1 day or 25mg / m2 intravenous infusion, 1 to 4 days; 21d for a cycle. The curative effect is evaluated once every 2 cycles. The toxic side effects are evaluated every cycle. 4 to 6 courses of chemotherapy; toxic side effects can not tolerate or disease progression are discontinued or changed to other programs. 【Results】 Thirty patients received 112 cycles in total, with a median of 4 cycles. CR1 (3.33%), PR9 (30.00%), SD15 (50.00%), and PD5 (16.67%) with an effective rate of 33.33% (10/30). The median time to disease progression was 7.5 months. One-year survival rate was 50.33% (16/30). Ⅲ, Ⅳ degree of adverse toxic side effects incidence of hair loss 26.67%; neutropenia 20.00%; nausea and vomiting 16.67%; thrombocytopenia 3.33%. 【Conclusion】 The combination of TXT and DDP as a first-line regimen for the treatment of advanced NSCLC is effective and well tolerated, which is worthy of clinical application.